Marijuana Is Everywhere. That’s a Problem.

More than a decade ago, legalising recreational marijuana felt like the progressive, overdue answer to decades of a punishing and deeply unequal war on drugs. Today, that answer looks increasingly incomplete. Across the United States, marijuana is not just legal in many states but has become inescapable. Without meaningful marijuana regulation, a public health problem is quietly taking hold.

From Criminal Offence to Cultural Fixture

Walk through Washington D.C., New York, or Denver on any given afternoon and the smell of cannabis is hard to miss. Dispensaries have become as familiar as coffee shops in states like Colorado. Celebrities openly boast about daily use. Products with names like “Trips Ahoy” and “Double Stuff Stoneos” sit on shelves, their packaging a deliberate nod to children’s biscuit brands.

None of this is simply legalisation. Cultural normalisation has happened on an extraordinary scale, with very little of the careful cannabis regulation that advocates once promised would accompany it.

German Lopez, an Opinion writer at The New York Times who has spent more than a decade covering drug policy, put it plainly. “It’s one thing to legalise a drug, but it’s another thing to culturally embrace it. And I think we have really culturally embraced it in a way that has surprised me.”

The Numbers Tell a Troubling Story About Marijuana Regulation

The shift in use patterns since legalisation is striking. More Americans now use marijuana daily than use alcohol daily, a remarkable reversal by any measure. According to national survey data, daily or near-daily cannabis users in the United States now exceed 17 million, outnumbering daily drinkers for the first time on record. Emergency room visits linked to cannabinoid hyperemesis syndrome, a condition involving severe and recurring nausea from heavy cannabis use, have risen sharply in legalised states. Addiction rates, long dismissed as impossible with marijuana, have climbed alongside them.

Users themselves are driving these findings. Growing numbers of people report in national surveys that they want to stop using cannabis but cannot, and that their use causes real harm in their daily lives. That is addiction by any reasonable definition.

Strains available today are also dramatically more potent than those of fifteen years ago, regularly catching users off guard. THC levels, the primary psychoactive compound in cannabis, have surged as the commercial market races towards stronger and more profitable products.

Big Weed Targets Its Heaviest Users

The marijuana industry is now worth tens of billions of dollars. At that scale, profit drives decisions, and in practice that means targeting the heaviest consumers. Research consistently shows a small share of very heavy users accounts for the majority of cannabis sales revenue, giving companies a powerful financial reason to sustain and encourage problematic use.

The playbook is familiar. Packaging mimics children’s snack brands. Marketing frames daily use as aspirational rather than risky. A cultural narrative positions cannabis as a wellness product or lifestyle virtue, rather than a substance carrying real and measurable harm.

“Corporations have a lot of incentives to market their products irresponsibly,” Lopez noted. “And that’s really not any different with weed.”

Federal prohibition currently limits how openly cannabis companies can advertise. No marijuana adverts appear during the Super Bowl. But that legal grey area will not last indefinitely, and the groundwork for a vastly more aggressive marketing machine is already in place.

Medical Cannabis Regulation Remains a Blind Spot

Problems extend well beyond recreational use. The medical marijuana market has largely bypassed the rigorous testing and evidence standards that govern every other pharmaceutical product in the United States. Dispensaries routinely make health claims that would not survive scrutiny if a conventional medication made them.

Early hopes that medical cannabis would prove effective across a wide range of conditions have not been borne out by rigorous clinical research. Genuine benefit exists for specific, narrow applications. Yet the broad therapeutic promises made to voters who backed medical marijuana initiatives have, in many cases, been substantially oversold.

Cannabis regulation in the medical sphere has been inconsistent at best. That inconsistency carries real consequences for patients trying to make informed decisions about their care.

What Stronger Marijuana Regulation Could Look Like

Nobody is arguing for recriminalisation here. Rolling back legalisation would return the country to a system that disproportionately criminalised Black, Latino, and low-income communities, handing out life-altering criminal records for conduct that wealthier populations faced far fewer consequences for. That would be a step backwards on both public health and justice grounds.

The real argument is for something that was always supposed to accompany legalisation but largely never came: robust, evidence-based marijuana regulation.

Taxation is the most direct lever. Decades of rising taxes on cigarettes, combined with advertising restrictions and public smoking bans, drove sustained reductions in tobacco use, particularly among young people. Marijuana taxes in most states remain remarkably low, sometimes amounting to cents on the dollar. Raising them, especially on high-potency products, would reduce the most harmful consumption patterns while leaving occasional users largely unaffected.

Taxing cannabis based on THC concentration, much as alcohol taxes distinguish between spirits and beer, would create a financial disincentive for the riskiest products. Over time, that pressure would shift the market towards lower-strength options. Restrictions on marketing aimed at under-18s are long overdue, as is a firm crackdown on packaging that deliberately mimics beloved children’s snack brands.

Those who worry that tighter cannabis regulation would push consumers back to the black market raise a fair point, but not a reason for inaction. No regulatory system achieves perfect compliance. The right question is whether regulation reduces harm overall, and the experience with alcohol and tobacco strongly suggests it does.

Grudging Toleration: A More Honest Standard for Cannabis Regulation

The criminologist Mark Kleiman offered a useful phrase for where drug policy ought to sit: “grudging toleration.” A society can permit something without celebrating it. Honesty about risk does not require punishment.

That is, more or less, how most liberal democracies approach alcohol and tobacco. Both remain legal. Both carry high taxes, advertising restrictions, and limits on where people can use them. Neither receives active cultural promotion as a lifestyle virtue.

Marijuana has instead been repositioned, through a combination of advocacy, commercial interest, and cultural drift, as something close to a health product. That repositioning helped build the political coalition needed to end a manifestly unjust prohibition. It no longer serves that purpose.

Legalise and regulate. That was always the promise. The first half has arrived in a growing number of states. The second half, meaningful marijuana regulation, remains largely unfinished business, and the public health cost of that gap is becoming harder to ignore every year.

Source: nytimes